CONTENTS:
- Clinical considerations for the management of xylazine overdoses and xylazine-related wounds [Editorial]. Sue K.L., Hawk K., p. 606-608.
- Does nitrous oxide addiction exist? An evaluation of the evidence for the presence and prevalence of substance use disorder symptoms in recreational nitrous oxide users [Addiction opinion and debate]. Back S., Kroon E., Colyer-Patel K., Cousijn J., p. 609-618.
- It is time to take nitrous oxide seriously without waiting for more evidence of harms. Allan J., Cameron J., Simpson H., Kor K., p. 619-620.
- Nitrous oxide: A difficult case for classification as an addictive substance. Brunt T.M., p. 621-622.
- Nitrous oxide: The label 'potentially addictive' may do more harm than good. Winstock A.R., p. 623-624.
- Yes, nitrous oxide addiction undeniably exists! Victorri-Vigneau C., Grall Bronnec M., p. 625-626.
- Nitrous oxide addiction or not, action is needed. A response to commentaries. Back S., Kroon E., Colyer-Patel K., Cousijn J., p. 627-628.
- Effectiveness of culturally tailoring smoking cessation interventions for reducing or quitting combustible tobacco: A systematic review and meta-analyses. Leinberger-Jabari A., Golob M.M., Lindson N., Hartmann-Boyce J., p. 629-648.
- Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis. De Santi O., Orellana M., Di Niro C.A., Greco V., p. 649-663.
- Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial. Bricker J.B., Santiago-Torres M., Mull K.E., Sullivan B.M., David S.P., Schmitz J., et al., p. 664-676.
- Health and economic burden of low back pain and rheumatoid arthritis attributable to smoking in 192 countries and territories in 2019. Chen N., Fong D.Y.T., Wong J.Y.H., p. 677-685.
- Smoking, vaping and drinking: A qualitative analysis of Aotearoa New Zealand young adults who tried e-cigarettes to stop smoking tobacco. Blank M.L., Hoek J., p. 686-695.
- Distributions of alcohol use and alcohol-caused death and disability in Canada: Defining alcohol harm density functions and new perspectives on the prevention paradox. Sherk A., Churchill S., Cukier S., Grant S.C., Shield K., Stockwell T., p. 696-705.
- Disentangling the contributions of alcohol use disorder and alcohol-related liver disease towards dementia: A population-based cohort study. Zhao S., Widman L., Hagström H., Shang Y., p. 706-716.
- Efficacy and safety of short-term edaravone or nerve growth factor add-on therapy for alcohol-related brain damage: A multi-centre randomised control trial. Wang H., Liu L., Zhou X., Guan Y., Li Y., Chen P., et al., p. 717-729.
- Health-care resource use among patients who use illicit opioids in England, 2010-20: A descriptive matched cohort study. van Hest N., Brothers T.D., Williamson A., Lewer D., p. 730-740.
- An on-line school-based substance use harm reduction programme: The Illicit Project randomized controlled trial results. Debenham J., Birrell L., Champion K.E., Newton N., p. 741-752.
- Longitudinal trajectories of substance use disorder treatment use: A latent class growth analysis using a national cohort in Chile. Borquez I., Cerda M., Gonzalez-Santa Cruz A., Krawczyk N., Castillo-Carniglia A., p. 753-765.
- Performance of International Classification of Disease-10 codes in detecting emergency department patients with opioid misuse. Chhabra N., Smith D., Pachwicewicz P., Lin Y., Bhalla S., Maloney C.M., et al., p. 766-771.
- Enhanced cannabis timeline followback (EC-TLFB): Comprehensive assessment of cannabis use including standard THC units and validation through biological measures. Petrilli K., Lawn W., Lees R., Mokrysz C., Borissova A., Ofori S., et al., p. 772-783.
- Commentary on Petrilli et al.: Assessing cannabis use in real-world settings - advances using standard THC units. Compton W., Weiss S., p. 784-785.
- Do we need clinical trials of high dose stimulant agonist treatment for stimulant use disorders? Hall W., Darke S., Farrell M., p. 786-787.
- Response to Hall et al.: Prescription psychostimulants for amphetamine-type stimulant use disorder - acknowledging challenges but not giving up on its potential cost-effectiveness. Sharafi H., Jutras-Aswad D., p. 788-789.